[go: up one dir, main page]

WO2002056941A2 - Methode de traitement de l'acrosyndrome - Google Patents

Methode de traitement de l'acrosyndrome Download PDF

Info

Publication number
WO2002056941A2
WO2002056941A2 PCT/US2002/003852 US0203852W WO02056941A2 WO 2002056941 A2 WO2002056941 A2 WO 2002056941A2 US 0203852 W US0203852 W US 0203852W WO 02056941 A2 WO02056941 A2 WO 02056941A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tranilast
catheter
patients
fistula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/003852
Other languages
English (en)
Other versions
WO2002056941A3 (fr
Inventor
Theodore M. Danoff
Jeffrey Granett
Diane K. Jorkasky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2002250044A priority Critical patent/AU2002250044A1/en
Publication of WO2002056941A2 publication Critical patent/WO2002056941A2/fr
Publication of WO2002056941A3 publication Critical patent/WO2002056941A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to a method for the prevention or reduction of vascular access dysfunction in mammals, including humans.
  • the method comprises administrating to a mammal, particularly a human patient, in association with the insertion, maintenance or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, into a vein, an effective oral or parental dose of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast) represented by the following formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • a mammal particularly a human patient
  • an effective oral or parental dose of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast) represented by the following formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the method comprises treating patients undergoing repair of their indwelling shunt or fistula or the vessels that feed or drain the shunt or fistula using surgery or percutaneous intervention, with or without stent placement, by administering to the subject an effective amount of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast) represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Tranilast N-(3',4'-dimethoxycinnamoyl)anthranilic acid
  • the present invention also relates to a method for the treatment of peripheral vascular disease in mammals, including humans.
  • the method comprises treating peripheral vascular disease, more specifically, a non-coronary artery that has undergone percutaneous intervention, with or without stent placement, in a mammal, particularly a human patient, by administering to the subject an effective amount of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast) represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Trnilast N-(3',4'-dimethoxycinnamoyl)anthranilic acid
  • vascular access dysfunction in hemodialysis patients is generally caused by outflow stenoses in the venous circulation.
  • Vascular access related morbidity accounts for about 23 percent of all hospital stays for advanced renal disease patients and contributes to as much as half of all hospitalization costs for such patients. Feldman H. I., J. Am. Soc. Nephrol. 7: 523 - 53 5 , 1996.
  • vascular access dysfunction in chemotherapy patients is generally caused by outflow stenoses in the venous circulation and results in a decreased ability to administer medications to cancer patients. Often the outflow stenoses is so severe as to require intervention.
  • TPN total parenteral nutrition
  • Tranilast is sold commercially as a drug for the treatment of allergic diseases, e.g., allergic bronchitis, allergic asthma, atopic dermatitis, and the like, based on the activity exhibited by the drug for inhibiting release of chemical mediators (The Journal of Allergy and Clinical Immunology. Vol. 57, No. 5, pp. 396-407, (1976)).
  • Tranilast inhibits fibroblast proliferation and collagen accumulation.
  • the '935 patent demonstrated that an extended period of Tranilast treatment was effective for lowering the incidence of post-surgery restenosis associated with PTCA. It was found that dosing patients with Tranilast for a period of at least about three months (i.e., a term of at least about 90 consecutive days of treatment, as used herein the phrase "at least three consecutive months" means at least 90 days) reduced the incidence of restenosis associated with the PTCA procedure. In one clinical study, when patients were administered Tranilast in a daily oral dose of 600 mg for three consecutive months after the PTCA procedure, the incidence of restenosis was less than about 20%. As reported in the '935 patent, the incidence of restenosis associated with the PTCA procedure usually is about 40%. The '935 patent does not contain any disclosure regarding the ability of Tranilast to effect vascular events as disclosed herein.
  • a treatment with Tranilast that demonstrates efficacy in the prevention or reduction of restenosis in a coronary artery does not correspond or lead one to anticipate with any degree of certainty that the treatment would have a beneficial or therapeutically significant effect on the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, into a vein in a mammal, particularly a human, in need thereof.
  • Tranilast is exhibiting a therapeutic effect on vessels other than coronary arteries. Further, nothing in the known art teaches or suggests that Tranilast could be efficaciously administered for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter into a vein. Further, nothing in the known art teaches or suggests that Tranilast could be efficaciously administered for the treatment of peripheral vascular disease in mammals, including humans.
  • Tranilast could be efficaciously administered for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, into a vein in a mammal, particularly a human, in need thereof.
  • Tranilast could be efficaciously administered for the treatment of peripheral vascular disease in mammals, including humans, in need thereof. It has now surprisingly been discovered that Tranilast can be suitably administered in the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter into a vein.
  • Tranilast can be suitably administered in the treatment of peripheral vascular disease in mammals, including humans, in need thereof.
  • This invention relates to a method for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, into a vein, or actual treatment, in a mammal, preferably a human, in need thereof, which comprises administering to the subject N-(3',4- dimethoxycinnamoyl)anthranilic acid or a pharmaceutically acceptable salt thereof in a dose of from about 0.1 mg to about 2,400 mg.
  • This invention relates to a method for the treatment of peripheral vascular disease in mammals, including humans, in need thereof, which comprises administering to the subject N- (3',4'-dimethoxycinnamoyl)anthranilic acid or a pharmaceutically acceptable salt thereof in a dose of from about 0.1 mg to about 2,400 mg.
  • prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter is meant that the incidence of vascular thrombosis and/or fistula failure and/or shunt failure and/or vascular access clotting and/or stenosis and/or restenosis and/or the need for declotting an indwelling vascular access shunt, fistula or catheter in Tranilast treated patients collected over the observation period are prevented or reduced in comparison to untreated patients.
  • the treatment with Tranilast can commence immediately, for example within 4 to 8 hours, after insertion or repair of the indwelling shunt, fistula or catheter, or actual treatment, such as dialysis treatment; within a few days, for example about 7 days, preferably about 1 or 2 days, after insertion or repair of the indwelling shunt, fistula or catheter, or actual treatment, such as dialysis treatment; or for a period of days, for example about 30 days, preferably about 14 days, preferably about 7 days, prior to insertion or repair of the indwelling shunt, fistula or catheter, or actual treatment, such as dialysis treatment.
  • in association with the insertion or repair of an indwelling shunt, fistula or catheter is a dosing protocol in which a dose or several doses, are skipped, for example in the morning of or on the day of insertion, repair or treatment.
  • in association with the insertion or repair of an indwelling shunt, fistula or catheter is a dosing protocol in which a day of drug treatment or several days of drug treatment, are skipped.
  • treatment when used herein to refer surgical procedures, are procedures selected from access surgery, placement of fistula or shunt, catheter insertion, actual disease treatment, such as dialysis treatment, and declotting of an access shunt, fistula or catheter. Further, treatment for insertion access also includes repair/revision of the access. For example, a patient experiencing a failure in a dialysis access shunt will have the access repaired, for instance, by angioplasty. Tranilast is useful after the repair to prevent restenosis.
  • treatment when used herein to refer to peripheral vascular disease, is meant prophylactic and therapeutic therapy.
  • peripheral vascular disease a non-coronary artery that has undergone percutaneous intervention, with or without stent placement, preferably, the intervention was due to a disease state selected form: renal artery stenosis; in cerebral vessels - carotid artery stenosis and vertebral arteries; and peripheral atherosclerosis in vessels, preferably the internal iliac artery, the femoral artery or in mesenteric vessels.
  • the dosing protocol for the treatment of peripheral vascular disease may be similar to that used in association with the insertion of an indwelling shunt, fistula or catheter, as described herein.
  • the present invention relates to a method for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment, into a vein in a mammal, particularly a human, or in the treatment of peripheral vascular disease in a mammal, particularly a human, which comprises administering to the subject N-(3',4'- dimethoxycinnamoyl)anthranilic acid (Tranilast) or a pharmaceutically acceptable salt thereof in a dose of from about 0.1 mg to about 2,400 mg.
  • N-(3',4'- dimethoxycinnamoyl)anthranilic acid Tranilast
  • a pharmaceutically acceptable salt thereof in a dose of from about 0.1 mg to about 2,400 mg.
  • the present invention further relates to a method for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment, into a vein in a mammal, particularly a human, which comprises administering to the subject N-(3',4'- dimethoxycinnamoyl)anthranilic acid (Tranilast) or a pharmaceutically acceptable salt thereof in a daily dose of from about 0.1 mg to about 2,400 mg for a treatment period of at least one week, preferably at least two weeks, in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment.
  • N-(3',4'- dimethoxycinnamoyl)anthranilic acid Tranilast
  • a pharmaceutically acceptable salt thereof in a daily dose of from about 0.1 mg to about 2,400 mg for a treatment period of
  • a preferred daily dosage amount of Tranilast for use in the present invention is about 25 mg to about 1,500 mg.
  • a more preferred daily dosage amount of Tranilast for use in the present invention is from about 100 mg to about 1,000 mg.
  • Particularly preferred is a daily dosage amount of from about 300 mg to about 900 mg of Tranilast for use in the present invention.
  • Particularly preferred is a daily dosage amount of about 600 mg of Tranilast for use in the present invention.
  • a contemplated treatment period for use in the present invention is about 85 days in association with the insertion or repair of an indwelling shunt, fistula or catheter, or actual treatment.
  • a contemplated treatment period for use in the present invention is about 70 days in association with the insertion or repair of an indwelling shunt, fistula or catheter, or actual treatment.
  • An additional contemplated treatment period for use in the present invention is about 50 days in association with the insertion or repair of an indwelling shunt, fistula or catheter, or actual treatment.
  • a preferred treatment period for use in the present invention is about 28 days in association with the insertion or repair of an indwelling shunt, fistula or catheter, or actual treatment.
  • An additional contemplated treatment period for use in the present invention is 14 days in association with the insertion or repair of an indwelling shunt, fistula or catheter, or actual treatment.
  • a preferred method of use in the current invention is a method for preventing or reducing vascular thrombosis and/or fistula failure and/or shunt failure and/or vascular access clotting and/or stenosis and/or restenosis and/or the need for declotting an indwelling vascular access shunt, fistula or catheter associated with insertion or repair of the indwelling shunt, fistula or catheter, or actual treatment, in dialysis patients.
  • a preferred method of use in the current invention is a method for preventing or reducing vascular thrombosis and or fistula failure and/or shunt failure and/or vascular access clotting and/or stenosis and/or restenosis and/or the need for declotting an indwelling vascular access shunt, fistula or catheter associated with insertion or repair of the indwelling shunt, fistula or catheter, or actual treatment, in cancer patients.
  • a preferred method of use in the current invention is a method for preventing or reducing vascular thrombosis and/or fistula failure and/or shunt failure and/or vascular access clotting and/or stenosis and/or restenosis and/or the need for declotting an indwelling vascular access shunt, fistula or catheter associated with insertion or repair of the indwelling shunt, fistula or catheter, or actual treatment, in total parenteral nutrition (TPN) patients.
  • TPN total parenteral nutrition
  • the efficacy of the presently invented method is demonstrated by the Examples below.
  • the invention also provides for the use of Tranilast or a pharmaceutically acceptable salt thereof in the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment, into a vein in a mammal, particularly a human, or in the treatment of peripheral vascular disease in a mammal, particularly a human, which comprises administering to the subject N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast) or a pharmaceutically acceptable salt thereof in a daily dose of from about 0.1 mg to about 2,400 mg for a treatment period of at least one week, preferably at least two weeks, in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment, or in the treatment of peripheral vascular disease in a mam
  • the invention also provides for a pharmaceutical composition for use in the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment, into a vein in a mammal, particularly a human, or in the treatment of peripheral vascular disease in a mammal, particularly a human, which comprises N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for use in the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, preferably a large bore catheter, or actual treatment, into a vein in a mammal, particularly a human, or in the treatment of peripheral vascular disease in a mammal, particularly a human, which comprises N-(3',4'-dimethoxycin
  • Tranilast is generally described in United States Patent 3,940,422. Tranilast and pharmaceutically acceptable salts and compositions thereof can be readily prepared by known methods such as described in United States Patent 3,940,422.
  • Tranilast or a pharmaceutically acceptable salt thereof When Tranilast or a pharmaceutically acceptable salt thereof is employed therapeutically, it can be administered orally or parentally in appropriate dosage forms, such as powder, granules, tablets, capsules, injectable solutions, and the like.
  • a Tranilast pharmaceutical composition can be formulated by admixing suitable carriers such as excipients, disintegrators, binders, brighteners, and the like, and preparing in accordance with conventional molding methods and dosage forms.
  • a powdered dosage form can be formulated by admixing Tranilast or a pharmaceutically acceptable salt thereof with suitable excipients, binders, brighteners, and the like.
  • Tablets can be formulated by admixing Tranilast or a pharmaceutically acceptable salt thereof with suitable excipients, disintegrators, binders, brighteners, and the like, and compressing the mixture with conventional molding equipment.
  • the tablets also can be coated to provide film coated tablets, sugar-coated tablets, enteric-coated tablets, and the like.
  • Capsules can be formulated by admixing Tranilast or a pharmaceutically acceptable salt thereof with suitable excipients, brighteners, and the like, and filling the mixture in capsules, or by forming granules containing Tranilast or a pharmaceutically acceptable salt thereof with conventional molding equipment, and filling the formed granules in capsules.
  • the daily or non daily dosage of Tranilast or a pharmaceutically acceptable salt thereof as an active ingredient will be an efficacious, nontoxic quantity selected from the range of about 0.1 mg to about 2,400 mg of active compound, preferably from about 25 mg to about 1,500 mg of active compound, preferably from about 100 mg to about 1,000 mg of active compound, particularly preferred is a dosage amount of from about 300 mg to about 900 mg, particularly preferred is a dosage amount of about 600 mg, per adult patient preferably by oral administration in association with dialysis treatment.
  • a treatment period of at least one week, preferably at least two weeks, is also contemplated herein.
  • the dosage and term of administration can be changed depending upon the weight and age and sex of the patient, the severity of the condition to be treated, and the like.
  • the above indicated dose may be split and administered preferably daily or from 1-6 times a month, preferably about 2 times a week, orally or parenterally.
  • parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral administration is preferred.
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
  • One hundred fifty prospective dialysis patients, who undergo successful insertion of an indwelling, large bore catheter, into a vein are selected for study. These patients are divided into two groups, and both groups do not differ significantly with sex, distribution of vascular condition or condition of lesions after insertion.
  • One group (about 50 patients) receives Tranilast in a daily dose of 600 mg (hereinafter identified as group I), and another group (about 100 patients) does not receive Tranilast (hereinafter identified as group II).
  • groups may also be given a calcium antagonist, nitrates and/or anti-platelet agents. These drugs are administered for 3 consecutive months following catheter insertion.
  • Tranilast in a daily dose of 900 mg, preferably in two 450 mg tablets administered 12 hours apart (hereinafter identified as group III), and another group (about 100 patients) does not receive Tranilast (hereinafter identified as group IV).
  • group III preferably in two 450 mg tablets administered 12 hours apart
  • group IV another group
  • patients may also be given a calcium antagonist, nitrates and/or anti-platelet agents. These drugs are administered every other day for 30 days following shunt insertion.
  • the comparative clinical data collected over the observation period of 12 months demonstrate the efficacy of every other day administration over 30 days Tranilast treatment for the prevention or reduction of vascular access dysfunction in patients after shunt insertion.
  • TPN total parenteral nutrition
  • One group (about 50 patients) receives Tranilast in a daily dose of 900 mg, preferably in two 450 mg tablets administered 12 hours apart (hereinafter identified as group VII), and another group (about 100 patients) does not receive Tranilast (hereinafter identified as group VIII).
  • groups may also be given a calcium antagonist, nitrates and/or anti-platelet agents. These drugs are administered for 30 consecutive days after fistula insertion.
  • One hundred fifty prospective cancer patients, who will undergo insertion of an indwelling catheter into a vein are selected for study. These patients are divided into two groups, and both groups do not differ significantly with sex, distribution of vascular condition or condition of lesions after insertion.
  • One group (about 50 patients) receives Tranilast in a daily dose of 100 mg, preferably in two 50 mg tablets administered 12 hours apart (hereinafter identified as group IX), and another group (about 100 patients) does not receive Tranilast (hereinafter identified as group X).
  • groups may also be given a calcium antagonist, nitrates and/or anti-platelet agents. These drugs are administered for 30 consecutive days following catheter insertion. The comparative clinical data collected over the observation period of 9 months demonstrate the efficacy of 30 days Tranilast treatment for the prevention or reduction of vascular access dysfunction in patients after catheter insertion.
  • Tranilast in a daily dose of 1200 mg, preferably in two 600 mg tablets administered 12 hours apart (hereinafter identified as group XI), and another group (about 100 patients) does not receive Tranilast (hereinafter identified as group XII).
  • groups may also be given a calcium antagonist, nitrates and/or anti- platelet agents. These drugs are administered for 6 consecutive weeks commencing 2 weeks prior to catheter insertion.
  • tranilast a daily dose of 900 mg, preferably in two 450 mg tablets administered 12 hours apart (herein referred to as group XIV).
  • group XIII tranilast
  • group XIV a daily dose of 900 mg, preferably in two 450 mg tablets administered 12 hours apart
  • the patency of the vessel is assessed at the time of catheter insertion, 1 month, 6 months and 1 year after catheter placement regardless of whether the catheter is removed from the vessel during the follow-up period.
  • the patency of the central vessels is assessed by ultrasonography, MRI and/or angiography.
  • the comparative clinical data collected over the observation period demonstrate the efficacy of 1 month Tranilast treatment for prevention or reduction of the degree of vessel stenosis in patients with indwelling catheters.
  • tranilast a daily dose of 600 mg, preferably in two 300 mg tablets administered 12 hours apart (herein referred to as group XVI).
  • group XV tranilast
  • group XVI a daily dose of 600 mg, preferably in two 300 mg tablets administered 12 hours apart
  • the tranilast is administered starting 4 days prior to access surgery and continued for 10 days following access surgery.
  • the patency of the venous outflow is assessed 1, 2, 3, 4 and 6 months after surgery and every 3 months thereafter until the access becomes unusable either due to clotting or inadequate flow.
  • the patency is assessed either by imaging techniques such as ultrasonography, angiography or MRI/MRA, or by functional techniques such as venous outflow pressures or by recirculation.
  • the comparative clinical data collected over the observation period demonstrate the efficacy of 2 weeks of Tranilast treatment for prolonging the period of good function of the arteriovenous shunt and/or slowing the rate of stenosis of the venous outflow tract of the shunt.
  • the arteriovenous shunts are used for hemodialysis access.
  • the patients are randomized into two groups. One group does not receive tranilast (herein referred to as group XVII) and the other group receives tranilast as a single oral 2000 mg dose at the time of the angioplasty (herein referred to as group XVIII).
  • group XVII tranilast
  • group XVIII group XVIII
  • the patency of the venous outflow is assessed 1, 2, 3, 4 and 6 months after surgery and every 3 months thereafter until the access becomes unusable either due to clotting or inadequate flow.
  • the patency is assessed either by imaging techniques such as ultrasonography, angiography or MRI/MRA, or by functional techniques such as venous outflow pressures or by recirculation.
  • the comparative clinical data collected over the observation period demonstrate the efficacy of a single dose of tranilast treatment for prolonging the period of good function of the arteriovenous shunt and/or slowing the rate of stenosis of the venous outflow tract of the shunt following angioplasty of a preexisting venous outflow obstruction.
  • the comparative clinical data collected over the observation period demonstrate the efficacy of a single dose of tranilast treatment for prolonging the period of good function of the femoral artery following angioplasty.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une méthode de prévention ou de réduction du dysfonctionnement de l'accès vasculaire associée à l'insertion ou réparation d'un shunt, d'une fistule ou d'un cathéter à demeure dans une veine, chez un mammifère, de préférence un être humain, ou sur une méthode de traitement de l'acrosyndrome chez un mammifère, notamment un être humain souffrant de cette pathologie, consistant à administrer au patient un acide N-(3', 4'-diméthoxycinnamoyl)anthranilique ou son sel pharmaceutiquement acceptable selon un dosage compris entre 0,1 mg et environ 2 400 mg.
PCT/US2002/003852 2001-01-19 2002-01-17 Methode de traitement de l'acrosyndrome Ceased WO2002056941A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002250044A AU2002250044A1 (en) 2001-01-19 2002-01-17 Method for the treatment of peripheral vascular disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26286101P 2001-01-19 2001-01-19
US60/262,861 2001-01-19
US26829301P 2001-02-13 2001-02-13
US60/268,293 2001-02-13
US26898601P 2001-02-15 2001-02-15
US60/268,986 2001-02-15

Publications (2)

Publication Number Publication Date
WO2002056941A2 true WO2002056941A2 (fr) 2002-07-25
WO2002056941A3 WO2002056941A3 (fr) 2003-03-27

Family

ID=27401546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003852 Ceased WO2002056941A2 (fr) 2001-01-19 2002-01-17 Methode de traitement de l'acrosyndrome

Country Status (2)

Country Link
AU (1) AU2002250044A1 (fr)
WO (1) WO2002056941A2 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] (COLUMBUS, OH, USA) CAPPER, E.A. ET AL.: 'Modulation of human monocyte activities by tranilast, ST 252218, a compound demonstrating efficacy in restenosis', XP002953930 Retrieved from STN Database accession no. 2001056667 & J. PHARMACOL. EXPER. THER. vol. 295, no. 3, December 2000, pages 1061 - 1069 *
DATABASE MEDLINE [Online] (COLUMBUS, OH, USA) MATSUMURA, T. ET AL.: 'Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast', XP002953929 Retrieved from STN Database accession no. 1999152078 & CIRCULATION vol. 99, no. 7, 23 February 1999, pages 919 - 924 *
DATABASE MEDLINE [Online] (COLUMBUS, OH, USA) MIYAZAWA, K. ET AL.: 'Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats', XP002953931 Retrieved from STN Database accession no. 96366138 & ATHEROSCLEROSIS vol. 118, no. 2, December 1995, pages 213 - 221 *

Also Published As

Publication number Publication date
AU2002250044A1 (en) 2002-07-30
WO2002056941A3 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
US11607389B2 (en) Delayed release deferiprone tablets and methods of using the same
WO2001062241A1 (fr) Procede permettant de prevenir ou reduire les dysfonctionnements de l'acces vasculaire
WO2002056941A2 (fr) Methode de traitement de l'acrosyndrome
US4575506A (en) Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
WO2000045810A1 (fr) Methode de prevention ou de reduction d'incidents cardio-vasculaires associes a une intervention coronarienne
AU748754B2 (en) Treatment of hepatic cirrhosis
WO2001093921A2 (fr) Administration d'un medicament anti-endotoxine par injection d'un bol ou par perfusion intraveineuse intermittente
WO2001097798A1 (fr) Procede servant a prevenir ou a reduire des evenements cardio-vasculaires induits par intervention coronarienne
EP1171116A1 (fr) Methode de prevention ou reduction d'incidents cardio-vasculaires associes a une intervention coronarienne

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP